PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced its financial results for the second quarter ended June 30, 2020 and provided a business update.
August 13, 2020
· 10 min read